Search Results 441-450 of 16901 for 4-week HIIT protocol

1. Ph 1b Study to Evaluate GSK2110183 in Combination with Bortezomib and Dexamethasone in Subjects with Multiple Myeloma - Mayo Clinic

   ... protocol from screening until four weeks after the last dose of study drug. Male subjects with female partners of childbearing potential must have had a ...

2. Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease - Mayo Clinic

   Participants who complete the study, or do not meet protocol response or remission criteria at Week 10 will have the option to enter a separate long-term ...

3. Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF - Mayo Clinic

   ... 4) phases. Phase 0 trials are small trials that ... Sponsor Protocol Number: RIV-HU6-2201. About this ... If treated with a loop or thiazide diuretic, must be on ...

4. A Study to Evaluate a New Method of Quantifying Muscle O2 Uptake and Blood Flow Using Near-Infrared Spectroscopy - Mayo Clinic

   Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines ...

5. A Study Using Spinal Stimulation During Exercise in Patients with Heart Failure - Mayo Clinic

   Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines ...

6. A Study to Evaluate the Combination of Binimetinib and Palbociclib in Treating Patients with KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer - Mayo Clinic

   ... 4 weeks. NOTE: Patients with thromboembolic events related to indwelling catheters or other procedures may be enrolled. Known history of acute or chronic ...

7. Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation - Mayo Clinic

   New York Heart Association class III or IV heart failure or a hospitalization for heart failure in the last 4 weeks. Patients with reduced ejection fraction ...

8. Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Systemic Sclerosis - Mayo Clinic

   Sponsor Protocol Number: CAB-201-003. About this ... Therapeutic pheresis within 4 weeks of Screening ... Note: Other protocol defined Inclusion/Exclusion Criteria ...

9. Evaluation of Exercise as Potential Prevention Strategy for Illicit Substance Relapses - Mayo Clinic

   Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

10. Cardiovascular Medicine - Clinical trials

    Treatment for FSGS is considered unsuccessful if the patient is unresponsive to standard therapy (e.g., at least 8 weeks of corticosteroids) and fails to ...